Susceptibility loci associated with prostate cancer progression and mortality

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2819-2832

  Gallagher, David J ^a   Vijai, Joseph ^a   Cronin, Angel M ^a   Bhatia, Jasmine ^a   Vickers, Andrew J ^a   Gaudet, Mia M ^b   Fine, Samson ^a   Reuter, Victor ^a   Scher, Howard I ^a   Halldén, Christer ^b,c   Dutra Clarke, Ana ^a   Klein, Robert J ^a   Scardino, Peter T ^a   Eastham, James A ^a   Lilja, Hans ^a,b,c   Kirchhoff, Tomas ^a   Offit, Kenneth ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

7JAZF1 GENE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENOTYPE; GLEASON SCORE; HUMAN; JEW; KLK3 GENE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS;

EID: 77952409133     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0028     Document Type: Article

References (49)

1. Ries LA, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88:2398-2424
2. Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246
3. Lilja H, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-436 (Pubitemid 350002992)
4. Shariat SF, et al. An updated catalog of prostate cancer predictive tools. Cancer 2008;113:3075-3099
5. Walz J, et al. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 2007;100:1254-1258 (Pubitemid 350043902)
6. Haiman CA, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638-644
7. Gudmundsson J, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281-283 (Pubitemid 351311771)
8. Eeles RA, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40:316-321 (Pubitemid 351311772)
9. Haiman CA, et al. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 2008;40:259-260 [author reply 260-1].
10. Gudmundsson J, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007;39:631-637 (Pubitemid 46676102)
11. Yeager M, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649 (Pubitemid 46676108)
12. Thomas G, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-315 (Pubitemid 351311773)
13. Cheng I, et al. 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet 2008;16:496-505. (Pubitemid 351420383)
14. Levin AM, et al. Chromosome 17q12 variants contribute to risk of early-onset prostate cancer. Cancer Res 2008;68:6492-6495
15. Zheng SL, et al. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007;99:1525-1533
16. Fitzgerald LM, et al. Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features. Clin Cancer Res 2009;15:3231-3237
17. Kote-Jarai Z, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008;17:2052-2061
18. Gayther SA, et al, The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. Cancer Res 2000;60:4513-4518
19. Kirchhoff T, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004;10:2918-2921 (Pubitemid 38619665)
20. Gallagher DJ, Gaudet MM, Pal P, et al. BRCA mutations, risk and outcome of prostate cancer. Clin Cancer Res 2010;16:2115-2121 2010 Mar 9. [Epub ahead of print].
21. Wiklund FE, et al. Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 2009;18:1659-1662
22. Penney KL, et al. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009;15:3223-3230
23. Salinas CA, et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009;69:363-372
24. Stephenson AJ, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006;24:3973-3978
25. Nielsen ME, et al. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion-"nadir + 2"? Urology 2008;72:389-93; discussion 394.
26. Klein RJ, HC, Cronin AM, et al. Blood biomarker levels to aid discovery of cancer-related single nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res. In press 2009.
27. Fine JP, GR. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
28. Mononen N, et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006;66:743-747 (Pubitemid 43165937)
29. Kader AK, et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009;69:1195-1205
30. Xu J, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A 2010;107:2136-2140
31. Huang SP, et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009;18:3068-3074
32. Lintula S, et al. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate 2005;63:324-329 (Pubitemid 40664343)
33. Steuber T, et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007;53:233-240 (Pubitemid 46338267)
34. Kattan MW, et al. The addition of interleukin-6 soluble receptor and transforming growth factor β1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21:3573-3579
35. Svatek RS, et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009;69:886-894
36. Winnes M, et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007;17:1033-1036
37. Nam RK, et al. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695 (Pubitemid 350249347)
38. Gopalan A, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406
39. Danila DC, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-7058 (Pubitemid 350276887)
40. de Bono JS, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14:6302-6309
41. Koontz JI, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A 2001;98:6348-6353
42. Ahn J, et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 2008;40:1032-4; author reply 1035-1036
43. Schroder FH, et al. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 2005;174:489-94; discussion 493-494 (Pubitemid 40981581)
44. Carter HB, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-1527 (Pubitemid 44680903)
45. Aus G, et al. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 2005;165:1857-1861 (Pubitemid 41352080)
46. Lai J, et al. PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis 2007;28:1032-1039 (Pubitemid 47072187)
47. Smaletz O, Scher HI. Outcome predictions for patients with metastatic prostate cancer. Semin Urol Oncol 2002;20:155-163 (Pubitemid 34522554)
48. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. In press 2010.
49. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27:2450-2456